AD-protect: Functional and mechanistic characterization of a new gene protecting from Alzheimer’s disease
Stefan Lichtenthaler (Germany), Jean-Charles Lambert (France), Julien Chapuis (France)

Investigating neuronal hyperactivity as a link between amyloid-β and tau spreading in Alzheimer’s disease
Robert Perneczky (UK),  Simon Bell (UK), Mikael Simons (Germany)

Neuronal Tau-RNA interactions in health and disease
Susanne Wegmann (Germany), Jernej Ule (UK), Karen Duff (UK)

Reducing the production of toxic Aβ peptides in Alzheimer’s disease by mutating the APP cholesterol-binding site: a new therapeutic strategy?
Marie-Claude Potier (France), Nicolas Villain (France), Henrik Zetterberg (UK)

LocalDementia: Local protein turn-over at synapses in dementia
Etienne Herzog (France), Jochem Herms (Germany) 

Does flavivirus infection trigger mitochondrial antigen presentation and autoreactive Tcell response in parkinsonism?
Annie Lannuzel (France), Michel Panisset (Canada)

NANOSYN: Unravelling synaptic pathology in Alzheimer’s disease and Dementia with Lewy bodies using super-resolution microscopy
Alberto Lleo (Spain), Tara Spires-Jones (UK)

Advancing adaptive deep brain stimulation for gait disturbances and freezing of gait in Parkinson’s disease
Huiling Tan (UK), Marie-Laure Welter (France)

Systematic investigation of genetic risk factors for neurodegenerative diseases in neuronal-microglia co-cultures using microfluidic devices
Peter Heutink (Germany), Jean Charles Lambert (France)

Adenosine A2A receptor: a switchable tool to study neuro-glial pathways in Tau related synapse loss
David Blum (France), Annett Halle (Germany)

CSPG targeting for lesion regeneration in multiple sclerosis
Bertrand Huard (France), V. Wee Yong (Canada)

Can a dysfunction of the basal ganglia and related low level nociceptive network underlie some central neuropathic pain symptoms in Parkinson’s disease?
Veronique Coizet (France), Paul Overton (UK)

Innate Memory-related blood Biomarkers as a proxy of microglia-mediated neurodegeneration to predict early AD progression (ADIMB)
Fabrizio Piras (Italy), Paul Edison (UK)

AD_GRIDS - altered grid cell computations in entorhinal cortex as a unique window into preclinical Alzheimer’s disease?
Thomas Wolbers (Germany), Mallar Chakravarty (Canada)

• Glypican4 as a target for innovative cell-based replacement therapy and as a biomarker in Parkinson’s disease Rosanna Dono (France), Mathias Bähr (Germany)
• Carbon-Model: Carbon metabolism systems analysis for the identification of disease and patient-specific metabolic and energetic defects in neurodegenerative diseases Jochen Prehn (Republic of Ireland), Daniele Bano (Germany)
• Neuropathological and Amyloid peptides differences between Down syndrome and familial Alzheimer’s disease with duplications and missense mutations in APP gene Marie-Claude Potier (France), Andre Strydom (UK), Henrik Zetterberg (UK)
• Gut microbes, Neuroinflammation and Alzheimer’s disease: determining the immunoregulatory role of gut microbiota on brain and behaviour Yvonne Nolan (Republic of Ireland), Annamaria Cattaneo (Italy), Sandrine Thuret (UK)
• Developing preclinical and clinical biomarkers of NRF2 pathway activation for therapeutic application in neurodegenerative diseases Pamela Shaw (UK), Antonio Cuadrado (Spain)
• Investigating chromatin landscapes in neurodegenerative disease models Paolo Salomoni (Germany), Giovanna Mallucci (UK)
• Is prion like propagation of alpha synuclein aggregation associated with a ferroptotic cell death David Devos (France), Alexander Storch (Germany), Nicola Pavese (UK)
• Investigating the interaction between ageing and immune dysfunction in LRRK2 Parkinson's disease Michela Deleidi (Germany), Francesca L’Episcopo (Italy)
• Focused ultrasound modulation of neuromelanin accumulation in a humanized rat model of Parkinson’s disease Miquel Vila (Spain), Stéphane Lehericy (France)

• Towards a unifying theory of Parkinson’s disease: Investigation of the biochemical and genetic role of Rab GTPases
  Dario Alessi (UK), Miratul Muqit (UK), Thomas Gasser (Germany)
• Protection of neurons in vitro and in vivo from Synuclein toxicity by molecular tweezers
  Erwan Bezard (France), Carlos Matute (Spain), Richard Wade-Martins (UK)
• Decoding Presymptomatic white matter changes in Huntington Disease (WIN-HD)
  Alexandra Durr (France), Sarah Tabrizi (UK)
• Synaptic correlates of learning and memory dysfunction analysed by super-resolution STED microscopy in the hippocampus in vivo
  Martin Fuhrmann (Germany), Daniel Choquet (France)
• GWAS in AD: focus on microRNA
  Sébastien Hébert (Canada), Jean-Charles Lambert (France), Luc Buée (France)
• BAFF/APRIL in the central nervous system
  Bertrand Huard (France), Stefan Lichtenthaler (Germany)    
• Therapeutic targeting of impaired lysosomal flux in Alzheimer’s disease
  Cora O’Neill (Republic of Ireland), Rebecca Sims (UK)
• Novel control of MT5-MMP on amyloidogenic and inflammatory pathways: validation in human iPSCs from Alzheimer patients and potential therapeutic perspectives
  Santiago Rivera (France), Alexander Dityatev (Germany)
• Identifying effectors of mutant C9Orf72 ALS/FTD to combat neurodegeneration
  Kevin Talbot (UK), Georg Haase (France)
• Using C. elegans to understand seeding and spreading of tau aggregation
  Rebecca Taylor (UK), Della David (Germany)
• Mito-ND: Mitochondrial Neurodegeneration
  Massimo Zeviani (UK), Peter Heutink (Germany)

Targeting glucocerebrosidase for disease-modifying treatments in Parkinson’s disease
Anthony H.V. Schapira (UK), David Park (Canada), Donato Di Monte (Germany) and Fabio Blandini (Italy)

WNT signaling: biomarker and target evaluation in Alzheimer’s disease
Antonio Cuadrado (Spain), James Woodgett (Canada) and Simon Lovestone (UK)

Mechanisms of amyloid-β clearance in models of vascular cognitive impairment and mixed dementia
Gabor Petzold (Germany) and Danica Stanimirovic (Canada)

In vivo neuronal cell reprogramming for a new regenerative approach in Parkinson’s disease
Vania Broccoli (Italy), Alexander Dityatev (Germany) and Josè Luis Lanciego (Spain) 

microRNA as novel therapeutic targets and disease biomarkers in Alzheimer's Disease, Frontotemporal dementia and Amyotrophic lateral sclerosis (NEURO-MIR)
Jochen Prehn (Ireland), Andre Fischer (Germany), Pierre Lau (Flanders), Jose Lucas (Spain)

Standards for determining the vascular contribution to neurodegeneration
Joanna Wardlaw (MRC), Martin Dichgans (DZNE), Dr Eric Smith (CIHR)

Integrated approach to identify novel genes for frontotemporal lobar degeneration
Marc Cruts (VIB), Christine Van Broeckhoven (VIB), Christian Haass (DZNE), Dieter Edbauer (DZNE) 

Mitochondrial dysfunction and susceptibility to Parkinson’s disease: New models of pathogenetic interactions
Donato A. Di Monte (DZNE), David S. Park (CIHR), Fabio Blandini (MDS), Anthony H.V. Schapira (MRC) 

Early synaptic plasticity and network dysfunction in transgenic (tg) rat models of Alzheimer’s disease (AD)
Michael Rowan (HRB/SFI), Claudio Cuello (CIHR), Martin Fuhrmann (DZNE),Michel Goedert (MRC) and Stefan Remy (DZNE)

Immune subtype in Parkinson disease
Thomas Gasser (DZNE), Antonio P. Strafella (CIHR)

C. elegans models of mitochondrial deficiency in the nervous system
Daniele Bano (DZNE), Siegfried Hekimi (CIHR), Mario de Bono (MRC)

The GENetic Frontotemporal Dementia Initiative (GENFI): a new multi-centre platform for the study of frontotemporal lobar degeneration
Martin Rossor (MRC), Giovanni B. Frisoni (MDS), Mario Masellis (CIHR)

Identification of generic supressors of proteinopathies
David Rubinsztein (MRC), Joerg Gsponer (CIHR)